Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Company profile
Company profile
Home  >  About us  >  Company profile

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000. On 19 August 2011, the company was listed on the Growth Enterprise Market of Shenzhen Stock Exchange (stock code 300255). At present, the registered capital is RMB 935 million yuan and the total assets are RMB 3.5 billion yuan. The company has four production bases, nine subsidiaries, two overseas companies, and two joint ventures. The company is a biochemical pharmaceutical enterprise, integrating research and development, production, sales, and import and export trade. It is a key high-tech enterprise with products from heparin crude products to low molecular weight heparin injections and a complete heparin industrial chain in the field of heparin, and a leading pharmaceutical company in the production of domestic heparin products.

  • 2000
    Company was founded in 2000
  • 2011
    Company was listed on the Growth Enterprise Market of Shenzhen Stock Exchange
  • 935
    The registered capital is RMB 935 million yuan
  • 3 . 5
    The total assets are RMB 3.5 billion yuan
  • Business purpose
    All for the health of mankind
  • Entrepreneurial spirit
    People-oriented, advocating science and technology, reputation first, pioneering and enterprising.
  • Business philosophy
    Integrity-based, mutual benefit
  • Quality policy
    Quality of survival, management for efficiency, integrity and reputation, innovation and development.
  • Management philosophy
    People-oriented, focus on implementation
  • Learning concept
    Systematic thinking, self-transcendence, lifelong learning, common progress.

Since its inception, the company has been researching, developing, manufacturing and marketing drugs for cardiovascular, cerebrovascular diseases and diabetes and anti-cancer drugs. The company has actively expanded its fields, including medical devices, beauty products, and precision medicine. The products are exported to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries in the world.

The company pays attention to the development of new drugs and has established the Changshan Pharmaceutical Institute of Pharmaceutical Research to build a new drug development and information sharing center. The institute plays the role of an innovative main body through the collection and analysis of the latest cutting-edge information on new drugs, the selection of key research and development varieties, the integration of various research and development resources, and the introduction and training of talents. This innovative main body has been serving the company's strategic goal of developing innovative drugs in the medium and long term, which is an important measure for implementing the company's strategy and significant for the company's future development. The company invests a large amount of money each year in technological innovation and has made major breakthroughs in innovation and cooperation.

In the next 1 to 3 years, low molecular weight heparin water-needle preparations will enter the European and American markets. The company will achieve the goal of “Double Hundred”: entering the top 100 Chinese pharmaceutical enterprises and sales revenue with an excess RMB 10 billion yuan. This will establish Changshan Pharmaceutical as a world-class enterprise for the research, development, and production of innovative new drugs.  In order to achieve these goals, we will continue to strengthen research and development investments based on existing product lines, and we will continue to increase innovative product projects with independent intellectual property rights.